Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease

Qiao Cheng, Dong Wang, Xiaoxuan Lai, Yin Liu, Yibo Zuo, Wenli Zhang, Lei Lei, Jia Chen, Hong Liu, Ying Wang, Haiyan Liu, Hui Zheng, Depei Wu, Yang Xu

Blood (2023) 141 (12): 1474–1488.

https://doi.org/10.1182/blood.2022017201

Published: 2023

Includes: Supplemental data

Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-141515

Published: 2020

Journal Articles

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Hongyu Zhang, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Qi Chen, PhD, Yuanzhen Cao, Kevin Pinz, Fang Liu, MD PhD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 2881.

https://doi.org/10.1182/blood-2019-122789

Published: 2019

Journal Articles

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Fang Liu, MD PhD, Hongyu Zhang, MD PhD, Xiao Wang, MD PhD, Yisong Xiong, PhD, Yuanzhen Cao, Yi Su, MD, Hai Yi, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 38.

https://doi.org/10.1182/blood-2019-122964

Published: 2019

Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc

Blood (2018) 132 (Supplement 1): 225.

https://doi.org/10.1182/blood-2018-99-114396

Published: 2018

NARROW

The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Email alerts

ASH Publications

American Society of Hematology

The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only